Genmab — November 2017
-
ADCT 301. Nu = Camidanlumab Tesirine !!! pts with HL have been treated with doses ≥30 µg/kg, with an ORR of 63.6% (14/22) and a complete response rate of 27.3% (6/22); ORRs by prior treatment were: 13/21 (61.9%) pts who previously received brentuximab vedotin (BV), 10/16 (62.5%) pts who previously received a checkpoint inhibitor and BV
-
-
Spændende når vi når 21. nov...
-
Accepteret late breaking med outstanding data på Alcyone er efter min mening den eneste kortsigtede kurstrigger.
-
The four STOMP presentations will include updated data from the arms evaluating selinexor in combination with Velcade
(bortezomib) and low-dose dexamethasone (SVd), selinexor in combination with Pomalyst (pomalidomide) and low-dose dexamethasone (SPd), and selinexor in combination with Revlimid (lenalidomide) and low-dose dexamethasone (SRd), and preliminary data from the arm evaluating selinexor in combination with Darzalex (daratumumab) and low-dose dexamethasone (SDd). -
-
Conclusions – Selinexor 100 mg QW, can be combined safely with daratumumab and dex. The activity observed in the first 3 pts is promising with all 3 pts responding to therapy. Enrollment is ongoing and updated data from 100 mg QW cohort, 100 mg QW expansion, and full phase 1 will be updated and presented.
-
Poseida Therapuetics paper on CAR-T; apparantly they are collaborating with J&J’s Janss
en to develop this... didn't know that... https://ash.confex.com/ash/2017/webprogram/Paper108439.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind